Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
D4190C00022
AstraZeneca AB
Hepatocellular Carcinoma
1 trial -
D419EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D5162C00048
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D516AC00003
AstraZeneca AB
Unresectable Non-small Cell Lung Cancer
1 trial -
D5336C00001
AstraZeneca AB
Triple Negative Breast Cancer
1 trial -
D533AC00001
AstraZeneca AB
Unresectable or Advanced Melanoma
1 trial -
D6132C00001
AstraZeneca AB
First-line patients with extensive disease small-cell lung cancer (SCLC)
1 trial -
D6186C00001
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
D6187C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D702KC00001
AstraZeneca AB
metastatic non-small cell lung cancer (NSCLC)
1 trial -
D7080C00001
AstraZeneca AB
Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma
1 trial -
D7407C00001
AstraZeneca AB
Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
1 trial -
D7986C00001
AstraZeneca AB
Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
D798KC00001
AstraZeneca AB
Solid Tumors, SQ, NSQ NSCLC
1 trial -
D798MC00002
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
D8220C00036
AstraZeneca AB
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
1 trial -
D822GC00001
AstraZeneca AB
Treatment Naïve Mantle Cell Lymphoma
1 trial -
D8410C00001
AstraZeneca AB
Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma
1 trial -
D8530C00002
AstraZeneca AB
Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
1 trial -
D9077C00001
AstraZeneca AB
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
1 trial -
D9102C00001
AstraZeneca AB
Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
1 trial -
D9106C00002
AstraZeneca AB
Non-small Cell Lung Cancer (NSCLC)
1 trial -
D933LC00001
AstraZeneca AB
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
1 trial -
D9520C00001
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9571C00001
AstraZeneca AB
Relapsed/Refractory Classical Hodgkin Lymphoma
1 trial -
D967LC00001
AstraZeneca AB
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer
1 trial -
D9720C00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D9720C00003
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9804C00001
AstraZeneca AB
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
1 trial -
DABRAFENIB , TRAMETINIB
Disc Medicine
ANAPLASTIC THYROID CANCER
1 trial -
DARATUMUMAB for Relapsed or Refractory Plasmablastic lymphoma
Fondazione Telethon ETS
Relapsed or Refractory Plasmablastic lymphoma
1 trial -
DAROTAXEL
Disc Medicine
metastatic castration-resistant prostate cancer
1 trial -
DC-CIK Immunotherapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
DC-VACCINE_IRSTIRCCS for Stage IV colorectal cancer
Istituto Gentili S.r.l.
Stage IV colorectal cancer
1 trial -
DC1 Vaccine
United Therapeutics Europe Ltd
Breast Cancer Female
1 trial -
DCC-3014-01-001
Lacuna Pharma Pty Ltd
Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
1 trial -
DCC-3084, DCC-3084
Lacuna Pharma Pty Ltd
Solid tumors driven by the MAPK Pathway
1 trial -
DCC-3116-01-001
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer, Metastatic Solid Tumor, Advanced Solid Tumor
1 trial -
DCVax-Direct
NORTHWEST BIOTHERAPEUTICS INC
Locally Advanced Tumor
1 trial -
DCVax-L and T Cells
NORTHWEST BIOTHERAPEUTICS INC
Ovarian Cancer
1 trial -
DEB-TACE+HAIC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma Non-resectable
1 trial -
DESTINY-Breast07
AstraZeneca AB
HER2-positive Metastatic Breast Cancer
1 trial -
DS-1062a
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
DS-3939a
Daiichi Sankyo
Metastatic Solid Tumor, Advanced Solid Tumor
1 trial -
DS-8201a
AstraZeneca AB
Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology
1 trial -
DS-8201a
Daiichi Sankyo
Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer
1 trial -
DS-8201a
AstraZeneca AB
HER2 Expressing Tumors
1 trial -
DS-8201a
Ningbo Cancer Hospital
Metastatic Breast Cancer HR+, HER2-
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.